TY - JOUR
T1 - Autologous T-cell vaccination for multiple sclerosis
T2 - A perspective on progress
AU - Vandenbark, Arthur A.
AU - Abulafia-Lapid, Rivka
N1 - Funding Information:
The authors wish to thank Ms Eva Niehaus for assistance in preparing the manuscript and acknowledge the support of the Yeshya Horowitz Association (New York, NY, USA), the National Institutes of Health (grant no. NS23221), the Nancy Davis MS Center Without Walls, and the Biomedical Laboratory R&D Service, Department of Veterans Affairs.
PY - 2008
Y1 - 2008
N2 - T-cell vaccination (TCV) is a unique approach to induce immune regulation that may have importance in the treatment of autoimmune diseases, including multiple sclerosis (MS). TCV employs a classic vaccine strategy of injecting an attenuated form of the disease-causing agent - in this case, myelin-reactive T cells - that have been selected and expanded from each MS donor and then re-injected after irradiation to induce protective immunity. This anti-T-cell immunity consistently results in selective deletion or regulation of the targeted pathogenic T cells in vivo. Longitudinal studies have established that TCV is safe and often results in a reduced relapse rate and clinical stability or improvement, at least temporarily, in the majority of treated MS patients. These results lend direct support to the involvement of inflammatory myelin-reactive T cells in the MS disease process. However, these hopeful trends reported in a number of pilot trials await validation in larger proof-of-principle trials that are now in progress.
AB - T-cell vaccination (TCV) is a unique approach to induce immune regulation that may have importance in the treatment of autoimmune diseases, including multiple sclerosis (MS). TCV employs a classic vaccine strategy of injecting an attenuated form of the disease-causing agent - in this case, myelin-reactive T cells - that have been selected and expanded from each MS donor and then re-injected after irradiation to induce protective immunity. This anti-T-cell immunity consistently results in selective deletion or regulation of the targeted pathogenic T cells in vivo. Longitudinal studies have established that TCV is safe and often results in a reduced relapse rate and clinical stability or improvement, at least temporarily, in the majority of treated MS patients. These results lend direct support to the involvement of inflammatory myelin-reactive T cells in the MS disease process. However, these hopeful trends reported in a number of pilot trials await validation in larger proof-of-principle trials that are now in progress.
KW - Immunomodulators, therapeutic use
KW - Multiple sclerosis, treatment
KW - Vaccines, therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=47049096574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47049096574&partnerID=8YFLogxK
U2 - 10.2165/00063030-200822040-00006
DO - 10.2165/00063030-200822040-00006
M3 - Review article
C2 - 18611069
AN - SCOPUS:47049096574
SN - 1173-8804
VL - 22
SP - 265
EP - 273
JO - BioDrugs
JF - BioDrugs
IS - 4
ER -